Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 735659, 5 pages
http://dx.doi.org/10.1155/2014/735659
Research Article

Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia

1Department of Neurology, Faculty of Medicine in Pilsen, Charles University in Prague, Husova 3, 301 66 Pilsen, Czech Republic
2Faculty Hospital in Pilsen, Alej Svobody 80, 304 60 Pilsen, Czech Republic
3Department of Histology and Embryology and Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Husova 3, 301 66 Pilsen, Czech Republic
4Department of Biology, Faculty of Medicine in Pilsen, Charles University in Prague, Husova 3, 301 66 Pilsen, Czech Republic
5Central Immunoanalytical Laboratory, Faculty Hospital in Pilsen, Dr. E. Benese 13, 305 99 Pilsen, Czech Republic

Received 30 September 2013; Accepted 18 December 2013; Published 9 January 2014

Academic Editor: Franco M. Buonaguro

Copyright © 2014 J. Polivka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction. Glioblastoma multiforme (GBM) is the most malignant primary brain tumor in adults. Recent whole-genome studies revealed novel GBM prognostic biomarkers such as mutations in metabolic enzyme IDH—isocitrate dehydrogenases (IDH1 and IDH2). The distinctive mutation IDH1 R132H was uncovered to be a strong prognostic biomarker for glioma patients. We investigated the prognostic role of IDH1 R132H mutation in GBM patients in West Bohemia. Methods. The IDH1 R132H mutation was assessed by the RT-PCR in the tumor samples from 45 GBM patients treated in the Faculty Hospital in Pilsen and was correlated with the progression free and overall survival. Results. The IDH1 R132H mutation was identified in 20 from 44 GBM tumor samples (45.4%). The majority of mutated tumors were secondary GBMs (16 in 18, 89.9%). Low frequency of IDH1 mutations was observed in primary GBMs (4 in 26, 15.3%). Patients with IDH R132H mutation had longer PFS, 136 versus 51 days ( , Wilcoxon), and OS, 270 versus 130 days ( , Wilcoxon test). Summary. The prognostic value of IDH1 R132H mutation in GBM patients was verified. Patients with mutation had significantly longer PFS and OS than patients with wild-type IDH1 and suffered more likely from secondary GBMs.